keyboard_arrow_up

Hyperlipidemia Research 2016 Covering 8 companies

In-detail Table of Contents of Hyperlipidemia Pipeline Market

Companies Involved in Therapeutics Development Acasti Pharma Inc., Allergan Plc, Alnylam Pharmaceuticals, Inc., Amgen Inc., Arbutus Biopharma Corporation, Arisaph Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, BASF SE, BCWorld Pharm Co. Ltd., Cadila Pharmaceuticals Ltd., Cardax Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., CJ HealthCare Corp., CymaBay Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Esperion Therapeutics, Inc., HanAll Biopharma Co., Ltd., Hanmi Pharmaceuticals, Co. Ltd., Huons Co., Ltd., Hyundai Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jeil Pharmaceutical Co., Ltd., Kowa Company, Ltd., LG Life Science LTD., Lotus Pharmaceutical Co., Ltd., Pfizer Inc., Pharmena SA, Prometheon Pharma, LLC, Protalix BioTherapeutics, Inc., Sancilio & Company, Inc., Thetis Pharmaceuticals LLC, Yuhan Corporation and Zydus Cadila Healthcare Limited

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Enquire before buying this research at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=521100 .

Scope for this research:

·         The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia

·         The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

·         The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects

·         The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

·         The report summarizes all the dormant and discontinued pipeline projects

·         The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

Complete research report at http://www.rnrmarketresearch.com/hyperlipidemia-pipeline-review-h1-2016-market-report.html .

List of Figures

·         Number of Products under Development for Hyperlipidemia, H1 2016

·         Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016

·         Number of Products under Development by Companies, H1 2016

·         Number of Products under Investigation by Universities/Institutes, H1 2016

·         Comparative Analysis by Late Stage Development, H1 2016

·         Comparative Analysis by Clinical Stage Development, H1 2016

·         Comparative Analysis by Early Stage Products, H1 2016

·         Assessment by Monotherapy Products, H1 2016

·         Assessment by Combination Products, H1 2016

·         Number of Products by Top 10 Targets, H1 2016

·         Number of Products by Stage and Top 10 Targets, H1 2016

·         Number of Products by Top 10 Mechanism of Actions, H1 2016

·         Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

·         Number of Products by Routes of Administration, H1 2016

·         Number of Products by Stage and Routes of Administration, H1 2016

·         Number of Products by Molecule Types, H1 2016

·         Number of Products by Stage and Molecule Types, H1 2016